Algiax Pharmaceuticals, today provided an update on its ongoing Phase 2a study (NCT04429919) with lead candidate AP-325 in patients with chronic neuropathic pain.
A small molecule drug candidate from Algiax Pharmaceuticals can reduce excitability of neurons in relation to chronic pain, dampening signal and reducing pain, a study shows.
Data Monitoring Committee recommends continuation of the study with no safety alerts within the study population Company is ramping up patient recruitment by doubling number of countries
Share this article
BOHEMIA, N.Y. and PITTSBURGH, April 30, 2021 /PRNewswire/ Scientific Industries, Inc. (OTCQB: SCND)
today announced the appointment of Dr. Jürgen Schumacher to the Company s Board of Directors.
Dr. Jürgen Schumacher is an internationally recognized German entrepreneur with more than 35 years of expertise in the biotech industry. Dr. Schumacher co-founded Qiagen AG, one of Germany s largest biotechnology companies, NewLab Bioquality AG, which was acquired by Charles River Laboratories International Inc., BiBiTech and Algiax Pharmaceuticals. Dr. Schumacher advises and invests in promising biotech business models.
Dr. Schumacher holds a PhD in Biology from Heinrich Heine University of Düsseldorf and a Diploma in Biology from Technical University of Darmstadt.
Scientific Industries Announces Appointment of Dr Jürgen Schumacher to the Board of Directors prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.